News
VRPX
3.100
+6.22%
0.182
Weekly Report: what happened at VRPX last week (0422-0426)?
Weekly Report · 3h ago
VRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023
Virpax Pharmaceuticals just reported results for the fourth quarter of 2023. The company did not report any revenue for the quarter. Virpax reported earnings per share of -$3.87. This was below the analyst estimate for -$2.70.
Investorplace · 4d ago
Weekly Report: what happened at VRPX last week (0415-0419)?
Weekly Report · 04/22 09:45
Virpax Pharmaceuticals files to sell common stock and warrants
Seeking Alpha · 04/18 20:45
12 Health Care Stocks Moving In Thursday's After-Market Session
Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. Biora Therapeutics, Mustang Bio and China SXT Pharmaceuticals were among the top gainers. Virpax Pharmaceuticals stock decreased by 18.2% during the session.
Benzinga · 04/18 20:31
*Virpax Pharmaceuticals to Offer Stock and Warrants
Dow Jones · 04/18 20:25
Weekly Report: what happened at VRPX last week (0408-0412)?
Weekly Report · 04/15 09:41
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Longeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. PetVivo Hldgs stock increased by 17.09% and SHL Telemedicine stock moved up by 13.26%. Losers include Supernus Pharmaceuticals and G1 Therapeutics.
Benzinga · 04/08 12:09
Weekly Report: what happened at VRPX last week (0401-0405)?
Weekly Report · 04/08 09:43
VIRPAX PHARMACEUTICALS INC - ON APRIL 2, GOT LETTER FROM NASDAQ STATING THAT COMPANY WAS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE
Reuters · 04/03 20:09
Weekly Report: what happened at VRPX last week (0325-0329)?
Weekly Report · 04/01 09:43
Virpax Pharmaceuticals’ Settlement Strain: Risk of Stalled Development and Hindered Growth
TipRanks · 03/27 06:01
12 Health Care Stocks Moving In Tuesday's After-Market Session
Apollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The company's, Q4 earnings came out today. Cara Therapeutics shares moved upwards by 7.36% and Iridex stock increased by 5.52%. Losers Akili and Mira Pharmaceuticals were the biggest losers in the market.
Benzinga · 03/26 21:32
Virpax Pharmaceuticals GAAP EPS of -$12.97 misses by $4.77
Virpax Pharmaceuticals GAAP EPS of -$12.97 misses by $4.77. As of December 31, 2023, Virpax had cash of approximately $9.1 million. The company expects to close out the year with a positive cash balance.
Seeking Alpha · 03/26 19:27
*Virpax Pharmaceuticals 2023 Operating Loss $15.2M>VRPX
Dow Jones · 03/26 11:32
Press Release: Virpax Pharmaceuticals Reports 2023 Year-End Results
Virpax Pharmaceuticals, Inc. Reports financial results for the twelve months ended December 31, 2023. The company is developing non-addictive products for pain management, post-traumatic stress disorder, and viral barrier indications. Virpax is on track to file the IND for Envelta(TM) later in 2024.
Dow Jones · 03/26 11:30
Press Release: Virpax Pharmaceuticals Reports -2-
Company's ability to successfully complete research and further development, and commercialization of Company drug candidates. The Company faces a number of risks and uncertainties. The Company's forward-looking statements speak only as of the date of this press release. The company has no obligation to update such statements.
Dow Jones · 03/26 11:30
*Virpax Pharmaceuticals Strong Start tp 2024 >VRPX
Dow Jones · 03/26 11:30
Weekly Report: what happened at VRPX last week (0318-0322)?
Weekly Report · 03/25 09:44
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Etao International Co (NASDAQ:ETAO) stock rose 249.4% to $0.5 during Tuesday's after-market session. The company's, Q4 earnings came out today. Taysha Gene Therapies shares moved upwards by 29.36%.
Benzinga · 03/19 21:34
More
Webull provides a variety of real-time VRPX stock news. You can receive the latest news about Virpax Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About VRPX
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.